Close Menu

What’s in a Name?

Premium

It’s true. PE is changing its name. The parent company of Celera Genomics and Applied Biosystems has been in dire need of a better handle ever since EG&G bought the right to spell-out Perkin-Elmer. In 1999, EG&G became Perkin-Elmer, and Perkin-Elmer was relegated to its own acronym. The confusion has been too much for customers to bear. (It’s still not uncommon to hear a technician refer to his “Perkin-Elmer 3700.”)

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.